Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...
On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US federal district courts, aligning with recent Delaware law changes, while the ...
Stocktwits on MSN
MRNA stock clocks best day in over two months on early-stage hantavirus vaccine research
Bloomberg reported on Friday that Moderna’s hantavirus research is “early-stage and ongoing” and began well before the cruise-ship cluster was identified. ・No hantavirus vaccine is currently approved ...
Learn more The open-session hearing comes just weeks ahead of the agency’s Aug. 5 target date to decide on the vaccine’s ...
The stock soared more than 700% through 2020 and into the first weeks of 2021, and peak vaccine sales reached more than $18 billion for the 2022 full year. But, as demand for coronavirus vaccines ...
Moderna (MRNA) stock pushed meaningfully higher on Friday following reports that the biotech giant is leveraging its mRNA platform to develop a vaccine for hantavirus. The news, which arrived after a ...
RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...
AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results